Evidence map›Paper›PMID 34021082›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities.

Qian Yin, Wong Yu, Caitlin L Grzeskowiak, Jing Li, Huang Huang, Jing Guo, Liang Chen, Feng Wang, Fan Zhao, Lotta von Boehmer and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Photoactivatable nanoagonists chemically programmed for pharmacokinetic tuning and in situ cancer vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Qian YinInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305.
Wong YuDepartment of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA 94305.
Caitlin L GrzeskowiakDivision of Hematology, Department of Medicine, School of Medicine, Stanford University, Stanford, CA 94305.ORCID 0000-0003-1550-4466
Jing LiInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305.
Huang HuangHHMI, Stanford University School of Medicine, Stanford, CA 94305.
Jing GuoDepartment of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA 94305.ORCID 0000-0002-6616-2585
Liang ChenInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305.
Feng WangHHMI, Stanford University School of Medicine, Stanford, CA 94305.
Fan ZhaoDepartment of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA 94305.ORCID 0000-0002-6103-5608
Lotta von BoehmerInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305.
Thomas J MetznerDepartment of Urology, School of Medicine, Stanford University, Stanford, CA 94305.
John T LeppertDepartment of Urology, School of Medicine, Stanford University, Stanford, CA 94305.ORCID 0000-0001-9980-3863
Yueh-Hsiu ChienInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305.
Calvin J KuoDivision of Hematology, Department of Medicine, School of Medicine, Stanford University, Stanford, CA 94305.ORCID 0000-0001-8401-9136
Mark M DavisInstitute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305; mmdavis@stanford.edu.
Stanford University · US

Funding

UCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALVIN J KUO · 2017 to 2026
$12.9M
Organoid-based Discovery of Oncogenic Drivers and Treatment Resistance MechanismsU01CA217851 · NCI · STANFORD UNIVERSITY · PI CURTIS, CHRISTINA N, JI, HANLEE P · 2017 to 2021
$4.7M
Howard Hughes Medical InstituteNCI NIH HHS U01 CA217851NCI NIH HHS U54 CA224081
6 · The paper itself

Abstract

Tumors are often infiltrated by T lymphocytes recognizing either self- or mutated antigens but are generally inactive, although they often show signs of prior clonal expansion. Hypothesizing that this may be due to peripheral tolerance, we formulated nanoparticles containing innate immune stimulants that we found were sufficient to activate self-specific CD8

Indexed as

AnimalsAntigensCD4-Positive T-LymphocytesCell Line, TumorHumansImmunity, InnateLymphocytes, Tumor-InfiltratingMelanoma, ExperimentalMiceNanoparticlesAntigenscancer immunotherapyinnate immune stimulationnanoparticlesperipheral toleranceself-antigen–specific tumor-infiltrating T cells

Identifiers

PMID34021082
PMCPMC8166076
OpenAlexW3161383343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.